Tansey Casey M purchased $797K of MOBI

Tansey Casey M purchased 68,559 shares of Mobia Medical, Inc. (MOBI) at an average of $11.63 ($11.51–$12.53, $0.80M total) across 4 trades over 2026-08-13 to 2026-08-17.

Original reporting
SEC EDGAR · Tansey Casey M
Published Aug 18, 2026, 1:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 2:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MOBI
Bullish
medium confidence
Mentioned
$MOBI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MOBIBullishLow
01

Why it matters

The newest information is the director’s open-market purchase details: 68,559 shares bought at $11.5073 to $12.5300, totaling $797,172.88, with post-transaction holdings of 301,891 shares.

02

Market read

Traders may treat the filing as a mild sentiment input, but it does not introduce new fundamentals like earnings, guidance, contracts, or regulatory actions.

03

What to watch

The article does not state whether the director’s purchase was part of a 10b5-1 plan (it says no), but it also provides no rationale, timing context, or follow-on selling behavior.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-17, covering buys from 2026-08-13 to 2026-08-17

Background

The article is a SEC Form 4 insider transaction disclosure for Mobia Medical, Inc. (MOBI).

Company-level read

Ticker impact

$MOBIBullishMedium confidence
Context

Director Tansey Casey M bought 68,559 shares of Mobia Medical for about $797K across four trades, per a new Form 4 filing.

Expected impact

Near-term impact is likely limited; any effect would be sentiment-driven rather than a re-rating catalyst.

Evidence & confidence

The filing provides transaction size, dates, and weighted average price, but no accompanying operational update, guidance, or deal terms.

Market effects

No sector-wide signal is provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine (compensation, diversification, or planned liquidity needs) and may not reflect a change in business outlook.

Key entities

  • Mobia Medical, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Tansey Casey M

    Director who executed the open-market purchase transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MOBIMed

What Mobia Medical (MOBI) Said on Its Q3 Earnings Call

Mobia Medical (MOBI) reported Q3 earnings with a net loss of $17.3M ($0.52 per share), improved from last year. Gross margin rose to 83.2%. Operating expenses increased to $31.5M due to higher personnel costs. The company cited positive impacts from revised stroke recovery guidelines and expects to publish clinical evidence in 2027.

$MOBIHigh

Mobia Medical Reports Third Quarter 2026 Financial Results

Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mobia Medical Reports Third Quarter 2026 Financial Results Delivers revenue growth of 73% in the third quarter and raises full year 2026 revenue guidance Austin, Texas, November 5, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke

$MOBIHigh

Mobia Medical stock jumps on stroke guideline inclusion

Mobia Medical Inc (MOBI) shares rose 7.2% premarket after the American Heart Association included its paired vagus nerve stimulation in 2026 stroke rehabilitation guidelines. The Vivistim Paired VNS System is the only FDA-approved system for this treatment, which may improve upper-limb function. Stroke is a leading cause of long-term disability in the U.S.